PERTH-BASED skins and burns treatment developer Clinical Cell Culture Ltd has announced managing director Troels Jordansen will be stepping down, while Professor Fiona Wood has rejoined the board. UK-based non-executive director David Imperiali also steps down from the board with immediate effect. The company said Mr Jordansen would remain with C3 until May 31 2006 to assist with an orderly transition. C3’s CFO and company secretary, Andrew Cannon, will become interim CEO as from June 1 2006, pending the appointment of a permanent CEO. C3 chairman Dalton Gooding said the re-appointment of Dr Wood as a non-executive director was an important move. “Our immediate priorities are achieving sales penetration in approved markets, managing regulatory approval processes especially in the United States, and restoring C3’s reputation in investor markets,” Mr Gooding said. “Fiona will play a vital role in all three areas in the months ahead.” The company recently reported a first-half operating loss of $5.6 million.